844. Efficacy and safety of abatacept in rheumatoid arthritis patients in Western region in Saudi Arabia: a multi-center study.
作者: Lina S Alahmadi.;Ahmed M Alhazmi.;Samaher I Alaauldeen.;Rand M Melibari.;Eman A Alsindi.;Reem M Hafiz.;Yara F Alqurashi.;Raghad A Alrowithi.;Hala M Albuti.
来源: BMC Rheumatol. 2025年9卷1期96页
Rheumatoid arthritis (RA) in adult patients, there is contradictory evidence regarding Abatacept's safety profile (ABA). This study aims to assess the safety and efficacy of ABA in adult patients in Saudi Arabia.
846. Early progression of capillaritis manifestations and poor renal outcome after induction therapy failure in microscopic polyangiitis.
作者: Boris Sorin.;Yann Nguyen.;Mary-Jane Guerry.;Patrice Cacoub.;Quentin Raimbourg.;Mathilde Nouvier.;Pierre Jourdain.;Marc Pineton de Chambrun.;Juliette Tennenbaum.;Ludovic Di Ascia.;Tamegnon Akoha.;Romain Paule.;Ludovic Trefond.;Alexandre Karras.;Loïc Guillevin.;Xavier Puéchal.;Benjamin Terrier.
来源: Rheumatology (Oxford). 2025年64卷11期5986-5989页 847. The incidence and mortality of connective tissue diseases: a population-level cohort study in England from 2012 to 2023.
作者: Samir Patel.;Mark D Russell.;Katie Bechman.;Maryam A Adas.;Zijing Yang.;Edward Alveyn.;Chris Wincup.;Alex Dregan.;Kate Bramham.;Sam Norton.;James B Galloway.;Patrick Anthony Gordon.
来源: Rheumatology (Oxford). 2025年64卷12期6151-6158页
The reported incidence and mortality of connective tissue diseases (CTDs) in England has been inconsistent in the literature. Our objective was to describe current trends in the incidence and mortality of systemic lupus erythematous (SLE), Sjögren's disease (SjD), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM) and mixed connective tissue disease (MCTD).
848. Targeting axial and peripheral psoriatic arthritis: a retrospective observational study on the clinical relevance of upadacitinib.
作者: Giuseppe Lopalco.;Eleonora Celletti.;Maria Morrone.;Fabiola Atzeni.;Massimiliano Limonta.;Maurizio Rossini.;Antonio Carletto.;Alberto Cauli.;Massimiliano Cazzato.;Maria Sole Chimenti.;Fabrizio Conti.;Cinzia Rotondo.;Pietro Leccese.;Roberta Foti.;Stefano Gentileschi.;Elisa Gremese.;Carlo Francesco Selmi.;Chiara Bazzani.;Giuliana Guggino.;Serena Guiducci.;Myriam Di Penta.;Alberto Lo Gullo.;Michele Maria Luchetti Gentiloni.;Serena Bugatti.;Roberta Ramonda.;Marco Sebastiani.;Angelo Semeraro.;Leonardo Santo.;Roberto Felice Caporali.;Florenzo Iannone.
来源: Rheumatology (Oxford). 2025年64卷12期6142-6150页
To evaluate upadacitinib (UPA) effectiveness on axial and peripheral manifestations of PsA by assessing the proportion of patients achieving low disease activity (LDA) and inactive disease (ID) status for axial involvement, and MDA and DAPSA-defined remission/LDA for peripheral domain.
849. Predicting the progression of interstitial lung disease associated with systemic sclerosis: despite progress, much remains to be done.
作者: Laurent Razat.;Mathilde Simon.;Sébastien Quétant.;Bruno Degano.
来源: Rheumatology (Oxford). 2025年64卷11期5595-5596页 851. Clinical and cost-effectiveness of a cycling and education intervention versus usual physiotherapy care for the treatment of hip osteoarthritis in the UK (CLEAT): a pragmatic, randomised, controlled trial.
作者: Thomas W Wainwright.;Tikki Immins.;Sharon Docherty.;Geoff Saunders.;Annie Hawton.;Elizabeth Goodwin.;Tim Rees.;Matthew Low.;Jo Samways.;Fran Webley.;Nikki Howard.;Paul H Lee.;Robert G Middleton.
来源: Lancet Rheumatol. 2025年7卷11期e764-e775页
Osteoarthritis of the hip is a leading cause of chronic disability. The cycling and education intervention (CLEAT) trial aimed to compare the clinical and cost-effectiveness of the cycling against hip pain (CHAIN) intervention, a group-based cycling and education programme, with usual physiotherapy care for patients with hip osteoarthritis referred for physiotherapy at a UK hospital.
852. IgG4-related disease with interstitial nephritis in a patient with metastatic melanoma following immune checkpoint inhibitor treatment: a case report.
作者: Thabuna Sivaprakasam.;Prachaya Nitchaikulvatana.;Jodi Gedallovich.;Jagruti Shah.;Matthew Charles Baker.
来源: BMC Rheumatol. 2025年9卷1期95页
Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of metastatic melanoma. Several case reports have documented IgG4-related disease (IgG4-RD) as an adverse event following ICI therapy. Here we report the first instance of interstitial nephritis associated with IgG4-RD as an immune-related adverse event (irAE) following ICI treatment.
855. Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial.
作者: Jacques Morel.;Emmanuelle Dernis.;Christian Roux.;Christophe Richez.;Olivier Brocq.;Bruno Fautrel.;Carine Salliot.;Olivier Vittecoq.;Xavier Mariette.;Frederic Lioté.;Slim Lassoued.;Cécile Gaujoux-Viala.;Arnaud Constantin.;Martin Soubrier.;Valérie Devauchelle-Pensec.;Vincent Goeb.;Jacques-Eric Gottenberg.;Hubert Marotte.;Anouck Rémy Moulard.;Claire Daien.;Gael Mouterde.;Cédric Lukas.;Joana Pissarra.;Helena Huguet.;Odile Launay.;Florence Galtier.;Marie Christine Picot.; .; .
来源: Lancet Rheumatol. 2025年7卷10期e675-e686页
Pneumococcal vaccination is recommended for patients with rheumatoid arthritis. Because immunosuppressant therapies for rheumatoid arthritis hinder vaccine efficacy, vaccination should be administered before initiating immunosuppressive drugs. We aimed to compare humoral responses in patients with rheumatoid arthritis receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before methotrexate initiation or simultaneously.
856. Sensorineural hearing loss in anti-interleukin-1 treated CAPS patients: risk factors and real-life barriers-an observational study.
作者: Özlem Satirer.;Anke Tropitzsch.;Assen Koitschev.;Toni Hospach.;Susanne M Benseler.;Jasmin B Kuemmerle-Deschner.
来源: Rheumatology (Oxford). 2025年64卷12期6359-6365页
To identify modifiable risk factors associated with progression of hearing impairment from a longitudinal cohort of anti-IL-1-treated children and adults with Cryopyrin-Associated Periodic Syndromes (CAPS) and explore real-life barriers to optimal long-term management.
857. Three-year follow-up of canakinumab dose extension in children with colchicine-resistant familial Mediterranean fever: PeRA-RG Experience.
作者: Gülşah Kavrul Kayaalp.;Şengül Çağlayan.;Kadir Ulu.;Şeyma Türkmen.;Fatma Gül Demirkan.;Vafa Guliyeva.;Gülçin Otar Yener.;Kübra Öztürk.;Ferhat Demir.;Semanur Özdel.;Mustafa Çakan.;Hafize Emine Sönmez.;Betül Sözeri.;Nuray Aktay Ayaz.; .
来源: Rheumatology (Oxford). 2025年64卷12期6366-6370页
Anti-interleukin-1 therapies are effective for colchicine-resistant FMF, yet data on optimal duration in pediatric patients remain limited. A previous multicentre study showed favourable outcomes with a standardized canakinumab dose extension protocol, though follow-up was short. This study aimed to assess the long-term outcomes of this protocol.
858. Biological therapies in paediatric Behçet's disease: results of an international collaborative study by the PRES Vasculitis Working Party.
作者: Özlem Akgün.;Fatma Gül Demirkan.;Isabelle Koné-Paut.;Taner Coşkuner.;Veysel Çam.;Merve Cansu Polat.;Esra Esen.;Emilio Amleto Conti.;Nihal Şahin.;Özge Baba.;Gülşah Kılbaş.;Nesibe Gökçe Kocamaz.;Sema Nur Taşkın.;Donato Rigante.;Marija Jelusic.;Annacarin Horne.;Kübra Öztürk.;Semanur Özdel.;Oya Köker.;Selçuk Yüksel.;Mukaddes Kalyoncu.;Hafize Emine Sönmez.;Giovanni Filocamo.;Ayşenur Paç Kısaarslan.;Maria Vincenza Mastrolia.;Banu Çelikel Acar.;Dallel Benazzouz.;Ezgi Deniz Batu.;Betül Sözeri.;David Saadoun.;Seza Özen.;Nuray Aktay Ayaz.
来源: Rheumatology (Oxford). 2026年65卷3期
This study aims to examine the indications for paediatric rheumatologists to use biologic therapies in childhood Behçet's disease (BD), as well as the efficacy, safety and remission rates of such treatments. We also compare demographic and clinical characteristics of Turkish and European cohorts.
859. Emphysema elevates the DETECT scores: impact on pulmonary hypertension screening and diagnosis in systemic sclerosis.
作者: Gesa M Sauer.;Florian Käs.;Carmen-Marina Mihai.;Muriel Elhai.;Rucsandra Dobrota.;Mike O Becker.;Sinziana Muraru.;Anna-Maria Hoffmann-Vold.;Oliver Distler.;Cosimo Bruni.
来源: Rheumatology (Oxford). 2025年64卷12期6132-6141页
Combined pulmonary fibrosis and emphysema (CPFE) predicts unfavourable outcomes in systemic sclerosis (SSc). CPFE and emphysema are associated with pulmonary function tests (PFTs) abnormalities. As screening algorithms for pulmonary hypertension include PFTs, we aimed to assess whether CPFE and emphysema affect the performance of the DETECT algorithm to select patients for right-heart catheterization (RHC).
860. More than a leaky gut: how gut priming shapes arthritis.
作者: Kristine A Kuhn.;Kentaro Yomogida.;Kathryn Knoop.;Hsin-Jung Joyce Wu.;Mario M Zaiss.
来源: Nat Rev Rheumatol. 2025年21卷9期513-525页
The gut microbiome forms an ecosystem that provides the host with numerous benefits such as digestion with nutrient generation, protection from pathogens and immune system maturation. Alterations in the microbial ecosystem associated with rheumatoid arthritis and spondyloarthritis have led to the gut-joint hypothesis, which postulates that these ecological changes cause immune dysfunction that contributes to the development of arthritis. Mechanisms by which dysbiosis might trigger arthritis include molecular mimicry, dysregulation of mucosal immunity, microbial translocation, production of immunomodulatory metabolites and immune cell trafficking. We discuss the data supporting each of these mechanisms, and highlight misconceptions, limitations and gaps in knowledge. In particular, we advise against the term 'leaky-gut' as the mechanisms and effects on the immune system of intestinal permeability and bacterial translocation are distinct. Nevertheless, rheumatoid arthritis and spondyloarthritis possibly result from the convergence of multiple pathways that could be unique to subgroups of individuals within these diseases. To move the field forward, each mechanism needs to be considered through the use of model organisms and interventional trials, individually and in concert.
|